-
H.C. Wainwright Reiterates Buy Rating on Biora Therapeutics (BIOR)
-
Biora Therapeutics (BIOR) Announces Supplemental Data from Phase 1 Clinical Trial of BT-600 as Presented at KOL Event
-
Biora Therapeutics (BIOR) Announces Positive Clinical Trial Results for BT-600

